Patents Examined by Brian Gangle
  • Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
    Patent number: 12109258
    Abstract: Provided herein are sequences of Plasmodium spp. liver stage exported proteins as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against malaria using the expression constructs provided herein.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 8, 2024
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Emma Reuschel, Bernadette Ferraro, Ahmed S. I. Aly
  • Bacterial extracellular vesicles
    Patent number: 12109243
    Abstract: Provided herein are methods and compositions related to EVs useful as therapeutic agents.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: October 8, 2024
    Inventors: Brian Goodman, Baundauna Bose, Christopher J. H. Davitt
  • Production of soluble recombinant proteins without N-terminal methionine in
    Patent number: 12104161
    Abstract: The present invention is directed to the cells, compositions and methods for the production of recombinant protein, wherein an f-met group on the 5?-terminus is enzymatically removed. In particular, the invention is directed to a production process for obtaining high levels of soluble recombinant CRM197 protein from E. coli. Cells preferably contain one or more mutations of disulfide reductase genes, so that disulfide reductase activity is reduced. The invention also relates to purification method for CRM197 as well as characterization of properly folded CRM197 protein.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: October 1, 2024
    Assignee: Fina Biosolutions LLC
    Inventors: Min-Ju Chang, Natalia Oganesyan, Andrew Lees
  • Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
    Patent number: 12097248
    Abstract: A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: September 24, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
  • Nanovesicles derived from bacteria of genus and use thereof
    Patent number: 12097227
    Abstract: Provided are vesicles derived from bacteria of the genus Lactococcus and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in samples obtained from patients with diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease and depression, compared with a normal individual, and the vesicles inhibited the secretion of inflammation mediators caused by pathogenic vesicles. Therefore, it is expected that the vesicles derived from bacteria of the genus Lactococcus can be effectively used for a method of diagnosing diabetes, myocardial infarction, atrial fibrillation, stroke, renal failure, Parkinson's disease or depression, and a composition for preventing or treating the disease or inflammatory disease.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: September 24, 2024
    Assignee: MD HEALTHCARE INC.
    Inventors: Yoon-Keun Kim, Hae-Sim Park
  • System and method for the detection and prevention of leukemia and lymphoma
    Patent number: 12091717
    Abstract: A method for detection and prevention of leukemia and lymphoma is disclosed. When mononuclear blood cells from an individual are exposed to a supernatant of a mycovirus-containing Aspergillus flavus, the degree and pattern of activation and upregulation or downregulation transcription factors are indicative of an individual's susceptibility to leukemia or lymphoma. Upon detection of observed transcription factors, preventive measures are provided to the individual. Preventive measures may include, for example, a vaccine, or may be provided upon detection of observed transcription factors with those individuals that are genetically susceptible to leukemia and lymphoma.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: September 17, 2024
    Inventor: Cameron Kamran Tebbi
  • Fecal microbiota composition for use in reducing treatment-induced inflammation
    Patent number: 12076350
    Abstract: The invention relates to the use of fecal microbiota transplant for preventing and/or reducing systemic and gut treatment-induced inflammation in an individual in need thereof.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: September 3, 2024
    Assignee: MaaT PHARMA
    Inventors: Emilie Plantamura, Cyrielle Gasc, Benoît Levast, Lilia Boucinha, Corentin Le Camus, Carole Schwintner, Hervé Affagard
  • Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
    Patent number: 12076380
    Abstract: A peptide consists of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence ALVEQGFTV (SEQ ID NO: 5), an adjuvant, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: September 3, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
  • Chemical sensor device and chemical sensor module
    Patent number: 12078610
    Abstract: A chemical sensor device includes a substrate; a chemical sensor element formed on the substrate and including a sensor surface exposed to mist; and a first water-absorbing member provided around the sensor surface on the substrate and including an opening that exposes the sensor surface.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: September 3, 2024
    Assignee: Kabushiki Kaisha Toshiba
    Inventor: Yoshiaki Sugizaki
  • Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
    Patent number: 12070491
    Abstract: A peptide consists of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214), an adjuvant, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: August 27, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
  • Method of treating cancer with a cancer therapy in combination with another therapeutic agent
    Patent number: 12070489
    Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a cancer therapy by treating the patient with said cancer therapy in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the cancer therapy, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the cancer therapy.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 27, 2024
    Assignee: Rappaport Family Institute for Research In the Medical Sciences
    Inventors: Yuval Shaked, Ziv Raviv, Dror Yeger
  • Anti-IL36R antibodies
    Patent number: 12060428
    Abstract: The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human Interleukin-36 receptor (IL36R). Methods for treating or preventing diseases mediated by IL36R (e.g., skin or colon inflammatory conditions such as palmo-plantar pustular psoriasis, palmoplantar pustulosis, generalized pustular psoriasis, ulcerative colitis or IBD) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: August 13, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jeanette Fairhurst, Elena Garnova, William Olson, Sokol Haxhinasto
  • Anti-angiogenesis fusion protein and uses thereof
    Patent number: 12054561
    Abstract: The present invention provides a bi-functional fusion protein, (AT)a-Fc-(VT)b, simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietins (ANGs), wherein AT is an ANG binding motif; and VT is a VEGF binding motif, Fragment crystallizable region (Fc) is an N-terminal of Immunoglobulin G (IgG); each of a and b is an integer from 1 to 10. The bi-functional fusion proteins contain two or more domains of human proteins and are of all human sequences, and thus are expected to be non-immunogenic, and potentially can be used therapeutically in human targeting angiogenesis-associated diseases.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: August 6, 2024
    Assignee: TRICAN BIOTECHNOLOGY CO., LTD
    Inventors: Huang-Tsu Chen, Jiun-Shyang Leou, Chung-Yuan Hsu, Cheng-Ke Li, Yun-Ting Wang, Li-Tsen Lin
  • Freeze-dried formulations including nanoparticles and methods of freeze-drying
    Patent number: 12042519
    Abstract: Provided are freeze-dried (FD) products of biological materials that have improved stability and reduced risk of collapse. The FD products include nanoparticles that are added to formulations including the biological materials prior to freeze-drying. Also described herein are methods of freeze-drying (FD).
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: July 23, 2024
    Assignee: The University of Chicago
    Inventors: Juan Jose de Pablo, Johnny D. Alfaro-Perez, Nader Taheri Qazvini
  • Anti-KLK5 antibodies and methods of use
    Patent number: 12037412
    Abstract: The invention provides anti-kallikrein-related peptidase 5 (KLK5) antibodies and methods of using the same.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: July 16, 2024
    Assignee: Genentech, Inc.
    Inventors: Cecilia P. C. Chiu, Hilda Y. Hernandez-Barry, David B. Iaea, Moulay Hicham Alaoui-Ismaili, James T. Koerber, Wei Yu Lin, Kelly Loyet, Yonglian Sun, Benjamin T. Walters, Jawahar Sudhamsu
  • Therapeutic treatment of skin disease with recombinant commensal skin microorganisms
    Patent number: 12036248
    Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: July 16, 2024
    Assignee: Azitra Inc
    Inventors: Azim Momin Munivar, Travis Michael Whitfill
  • Recombinant for increasing yield of menaquinone 7 and application thereof
    Patent number: 12037576
    Abstract: The present disclosure provides a recombinant Bacillus subtilis for increasing the yield of menaquinone 7 (MK-7) and application thereof, and belongs to the field of genetic engineering. In the present disclosure, 14 recombinant strains BS1-BS14 are constructed through the modification of genes related to the biosynthetic pathway of MK-7 on a chromosome of Bacillus subtilis, wherein BS6-BS14 significantly increase the yield of the MK-7, reaching up to 33.5 mg/L, which is 3.53 times the yield of the original strain of wild-type Bacillus subtilis 168. The present disclosure further provides a method for modifying the MK-7 biosynthetic pathway in microorganisms to increase the yield of the MK-7, providing a theoretical basis for constructing a high-yielding strain of the MK-7.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: July 16, 2024
    Assignee: NANTONG LICHENG BIOLOGICAL ENGINEERING CO. LTD
    Inventors: Hongzhi Xia, Long Liu, Qinqing Gu, Jiangbo Li, Shixiu Cui, Xueqin Lv, Jianghua Li, Guocheng Du, Jian Chen
  • Cationic neurotoxins
    Patent number: 12037369
    Abstract: The present invention provides engineered clostridial toxins comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point (pi) of the engineered clostridial toxin to a value that is at least 0.2 pi units higher than the pi of an otherwise identical clostridial toxin lacking said at least one amino acid modification, and wherein said at least one amino acid modification is not located in the clostridial toxin binding domain (Hc domain). Also provided are medical uses of the engineered clostridial toxins.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: July 16, 2024
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventors: Dina Brady Anderson, Gavin Stephen Hackett, Sai Man Liu
  • Probiotics useful for eradicating helicobacter pylori infection
    Patent number: 12029768
    Abstract: New probiotic clones have been obtained having enhanced activity against Helicobacter pylori infection. The new clones are derived from selected strains of Lactobacillus acidophilus and Bifidobacterium animalis lactis sp. They are advantageously non-susceptible to antibiotics currently used in the treatment of Helicobacter pylori infection, which makes them ideal for co-treatment with said antibiotics in the eradication of Helicobacter pylori infection. Synergistic effects of combinations among the present probiotics and their strong adjuvant effect on the activity of antibiotics on Helicobacter pylori are herein reported.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: July 9, 2024
    Assignee: DACF S.R.L.
    Inventor: Berardino Vaira
  • Method for lateral flow immunoassay
    Patent number: 12031983
    Abstract: The present disclosure relates to a novel method for lateral flow immunoassay (LFIA) by utilizing plasmonic enhancement strategy. More specifically, the present disclosure provides a plasmonic enhanced lateral flow sensor (pLFS) concept by introducing a liposome-based amplification of the colorimetric signals on the lateral flow platform for ultrasensitive detection of pathogens.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: July 9, 2024
    Assignee: Purdue Research Foundation
    Inventors: Joseph Irudayaraj, Wen Ren